Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 9, 2014, Pages 1440-1448

  Cugno, M ^a   Gualtierotti, R ^a   Possenti, I ^b   Testa, S ^b   Tel, F ^b   Griffini, S ^a   Grovetti, E ^a   Tedeschi, S ^b   Salardi, S ^b   Cresseri, D ^b   Messa, P ^b   Ardissino, G ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Atypical hemolytic uremic syndrome; Complement; Complement component 5; Eculizumab; Thrombotic microangiopathies

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; ECULIZUMAB; HAPTOGLOBIN; LACTATE DEHYDROGENASE; MANNOSE BINDING LECTIN; MEMBRANE COFACTOR PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MONITORING; DRUG SAFETY; FEMALE; FOLLOW UP; HEMOLYTIC UREMIC SYNDROME; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAINTENANCE THERAPY; MALE; NUCLEOTIDE SEQUENCE; REMISSION; TREATMENT DURATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CHEMISTRY; GENETICS; HEMOLYSIS; KIDNEY TRANSPLANTATION; METABOLISM; MUTATION; PRESCHOOL CHILD; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOTIC MICROANGIOPATHIES; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; COMPLEMENT C3; COMPLEMENT C5; COMPLEMENT FACTOR H; FEMALE; HEMOLYSIS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MUTATION; PLATELET COUNT; REMISSION INDUCTION; THROMBOTIC MICROANGIOPATHIES; TIME FACTORS; YOUNG ADULT;

EID: 84908495607     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12615     Document Type: Article

References (19)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-87.
2. Hodgkins KS, Bobrowski AE, Lane JC, Langman CB. Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol 2012; 35: 394-400.
3. Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program 2011; 2011: 15-20.
4. Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010; 25: 2431-42.
5. Józsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007; 110: 1516-18.
6. Kavanagh D, Richards A, Goodship T, Jalanko H. Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36: 653-9.
7. Waters AM, Licht C. aHUS caused by complement dysregulation:new therapies on the horizon. Pediatr Nephrol 2011; 26:41-57.
8. Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552-9.
9. Nürnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-4.
10. Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Nöel L-H, Hourmantj M, Niaudet P, Fremeaux-Bacchi V, Rondeaul E, Legendrea C, Loirat C; French Study Group for Atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12: 3337-54.
11. Zimmerhackl LB, Hofer J, Cortina G, Mark W, Wurzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 362: 1746-8.
12. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 1325-9.
13. Salant DJ. Targeting complement C5 in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2011; 22: 7-9.
14. Goicoechea de Jorge E, Paixao-Cavalcante D, Rose KL, Tedesco F, Cook HT, Botto M, Pickering MC. The development of atypical haemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011; 22: 137-45.
15. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010; 31: E1445-60.
16. Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, Marks JD, Bradbury A, Tedesco F. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol 2002; 32:2773-82.
17. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009; 373: 759-67.
18. Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc 2012; 44: 3037-40.
19. Heinen S, Pluthero FG, van Eimerenb VF, Quaggina SE, Licht C. Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Mol Immunol 2013; 54: 84-8.